Introduction
============

Summary of Microbial Activities in Human Metabolism
---------------------------------------------------

Knowledge of the microbial communities living in human body is increasing at a fast pace. The Human Microbiome Project demonstrated that humans might be considered superorganisms, composed of human and microbial components, interacting in a symbiotic manner ([@B80]). Microbial population has coexisted with humans in a state of mutually beneficial cohabitation and plays an important role in health and disease ([@B14]). Inter-organismal crosstalk interruption leads to profound and diverse cellular and metabolic changes observed in gut dysbiosis ([@B31]). Gordon et al. showed that the composition of the gut microbiome affects metabolism and energy homeostasis ([@B41]; [@B80]). The gut microbiome is a biotic factor regulating body weight, and thus linked to obesity and other metabolic disorders ([@B42]) and ([@B14]). Maintaining the symbiotic equilibrium between gut microbiome and host in different pathological conditions remains a challenge for the physicians. The understanding of their interaction, manipulation of the structure and functions of human microbiota may allow effective prevention and treatment of many diseases.

Small Intestinal Bacterial Overgrowth may Triggers CKD/ESRD
-----------------------------------------------------------

Dysbiosis can be promoted by any inflammatory reaction, making it difficult to discern cause and consequence of the disease ([@B65]; [@B2]). The gut microbiome could be a trigger for the deregulated immune system in kidney disease ([@B2]).

[@B2] pointed out that the metabolic alterations of uremia favor gut pathogen overgrowth. But this fact has been largely neglected as a trigger for chronic kidney disease (CKD)/end-stage renal disease (ESRD)-related immune derangements ([@B50]). The concept was that pathobiont overgrowth induces inflammation and loss of barrier function that, results in increased translocation of bacterial components such as LPS and other immune stimulating proteins. This process activates innate immunity characterized by production of pro-inflammatory cytokines and modulates a number of clinically relevant processes in CKD such as the progression of CKD, accelerated atherogenesis, and protein wasting ([@B2]). Data from a previous studies indicated that toxic products generated by a dysbiotic gut microbiome may contribute to progression of CKD and CKD-related complications ([@B75]; [@B91]; [@B61]). As a result, a hypothesis was developed that probiotics and prebiotics reduce progression of CKD and associated uremia by optimizing the gut microbiome ([@B43]).

With a comprehensive understanding of the structure, density, and function of the gut microbiota, new therapeutic targets could be identified and utilized for a healthier gut. A healthy gut could help improve overall well-being ([@B88]) including health improvement for children with acute and chronic renal conditions.

During development, human microbiome stimulates and synchronizes with the host innate immune functions by the classical complement pathway, the alternate pathway, and the mannose-binding lectin pathway. Kidney disease such as atypical hemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis are closely linked to abnormalities in complement activation due to host genetic anomalies ([@B77]). Animal experiments have also established that the microbiota modulate the expression of host genes ([@B5]). Moreover gnotobiotic mouse models revealed that different members of the microbiota induce different types of immune responses ([@B32]). A mixture of *Clostridium* sp. demonstrated induction of FoxP3+ regulatory T cells and the segmented filamentous bacteria promoted T helper type 17 cell differentiation ([@B72]). Animal models have advanced our understanding of the role of microflora in human disease. However, animal conditions can only mimic the features of human disorders ([@B56]). The gut microbiota produces uremic toxins such as advanced glycation end-products, phenols \[e.g., *p*-cresyl sulfate (PCS)\], and indoles \[e.g., indoxyl sulfate (IS); [@B11]; [@B78]; [@B29]\]. Animal studies have shown that the biological effect of these molecules include induction of pro-inflammatory responses, leukocyte stimulation, and endothelial dysfunction. These conditions play a substantial role in the development and progression of multiple causes of acute kidney injury (AKI) and CKD ([@B16]; [@B55]; [@B67]; [@B45]). IS and PCS are renal and cardiovascular toxins, produced solely by the gut microbiota, which have pro-inflammatory and pro-oxidative properties ([@B23]). Animal studies have shown that uremic toxins may promote the progression of chronic renal failure by damaging tubular cells ([@B63]).

Many reports showed that the composition of gut microbiota is different in CKD patients. [@B85], using a rat model, showed CKD alters the composition of intestinal microbial flora ([@B18]). The study revealed substantially less species richness as measured by the number of operational taxonomic units (OTUs) in the nephrectomized rats compared with the controls ([@B85]). The mechanism of bacterial gut alteration was thought to be the result of multiple factors including, but not limited to, metabolic acidosis, volume overload, intestinal wall congestion retention, uremia, frequent use of antibiotics, oral iron, and intestinal ischemia ([@B36]; [@B51]; [@B85]). Animal experiments also showed that persistent inflammation contributed to the high rates of CKD development ([@B84]; [@B76]).

Some thought that a healthy high fiber diet might promote significant colonization with Shiga toxins-producing *Escherichia coli*, which can lead to hemolytic-uremic syndrome (HUS; [@B32]). Interesting work by [@B24], showed that the probiotic *Lactobacillus reuteri* (ATCC PTA 6475) was effective in suppressing disease symptoms of HUS. Their data indicated that *L. reuteri* partially protected mice from disease manifestations ([@B24]). The progression of CKD was hindered by 'enteric dialysis' by administering non-pathogenic soil-borne alkalophilic urease-positive bacterium *Sporosarcina pasteurii* (Sp) in 5/6 nephrectomized rats. That pilot study demonstrated that rats fed with 10^9^ cfu/day of live Sp had reduced blood urea-nitrogen levels and showed significantly prolonged lifespans ([@B49]). Furthermore, in germ-free mice that are lacking in immune related to inflammation, the gut microbiome was found to influence kidney homeostasis with elevated levels of key cell volume regulators (betaine, choline, and myo-inositol) in kidneys ([@B62]).

Obesity and metabolic disorders link tightly to kidney disease. Studies in mice demonstrated that an interrelationship exists between energy balance, diet, and the composition of the gut microbial community. This interrelationship might have significant clinical implications including obesity related complications ([@B5], [@B6]; [@B40]; [@B81]; [@B19]). In a murine model, gut microbiome product PCS interfered with intracellular insulin signaling pathways and triggered insulin resistance. The treatment of CKD mice with a prebiotic reduced the intestinal production and blood levels of PCS and prevented insulin resistance and lipid abnormalities ([@B79]).

To improve animal models to study the human microbiome, a gnotobiotic piglet model was developed ([@B89]) furthermore human microbiota-associated (HMA) piglets have been established using inocula from infants, children, and adults. The gut microbiota of recipient HMA piglets was more similar to that of the human donor than that of conventionally reared piglets harboring a pig microbiota. Moreover, *Bifidobacterium* and *Bacteroides*, two predominant bacterial groups of the infant gut, had been successfully established in the HMA piglets.

What did we Learn About Gut Microbiome and Renal Function From Animal Studies?
==============================================================================

Understanding impact of gut microbiome and pathobiome in renal pathology might bring a critical new knowledge in understanding genesis and treatment of kidney disease. The metagenomics approach has the potential to uncover entirely novel genes, gene families, and their encoded proteins, which might be of biotechnological and pharmaceutical relevance ([@B8]). Therefore, animal models strongly proved impact on gut microbiome and renal function, in addition suitable animal models were created to pursue relevant study in pediatric population.

Gut Microbiome and Renal Axis in Adult Population
=================================================

An adult human's microbiome is diverse and dependent upon health status, diet, and geographic location. The gut harbors a complex mixture of tens of trillions of microbes, comprised of more than 1,000 diverse species of identified bacteria with over three million genes. In healthy individuals, the phyla Bacteroidetes and Firmicutes contribute \>90% of all species, including abundant bacterial genera such as *Bacteroides* sp., *Alistipes* sp., *Prevotella* sp., *Porphyromonas* sp., *Clostridium* sp., *Dorea* sp., *Faecalibacterium* sp., *Eubacterium* sp., *Ruminococcus* sp., and *Lactobacillus* sp. Other less abundant phyla include the Actinobacteria (that is, *Bifidobacterium* sp. and *Collinsella* sp.), Proteobacteria (that is, *Enterobacteriaceae, Sutterella* sp., and *Helicobacter* sp.), Verrucomicrobia (that is, *Akkermansia* sp.), and some others ([@B60]).

The microbiota colonizing the gut control the normal development and function of the mucosal barriers, support food digestion, and defend the individual from circulation of pathogenic micro-organisms. On the other hand, the break down of proteins and peptides by colonic microorganisms yields a great diversity of end-products, many of which have toxic properties ([@B47]).

Adult uremic patients show greatly increased counts of both aerobic and anaerobic organisms in the duodenum and jejunum, portions of the intestines not normally colonized heavily by bacteria in healthy persons ([@B61]). With diminished kidney clearance, quantitative, and qualitative alterations in gut microbiota were noted in adult patients with CKD and ESRD ([@B30]; [@B69]; [@B86]). [@B86] showed significant differences in the abundance of 190 microbial OTUs between the patients with ESRD and the normal control individuals. In addition, hemodialysis patients had significantly lower numbers of *Bifidobacteria* and higher *Clostridium perfringens* numbers ([@B63]).

Intestinal microbial flora in patients with CKD characterized by decreases in both *Lactobacillaceae* and *Prevotellaceae* families have been reported ([@B48]). As a result, uremic toxins produce bacteria families' over growth that impacts immune response and inflammatory reactions. Study in 149 CKD patients with a mean estimated Glomerular Filtration Rate (eGFR) of 40 ± 9 mL/min/1.73 m^2^ showed that serum free and total IS were independently associated with increased levels of serum IL-6, TNF-α, and IFN-γ, whereas serum free and total PCS were independently associated with increased levels of serum IL-6 and pulse wave velocity ([@B63]). This study for the first time proved a strong connection between produced and retained uremic toxins and demonstrated strong predictors of cardiovascular mortality in CKD patients. The idea was further supported by a publication of [@B48]. They also provided a concise description of the potential role of the CKD-associated changes in the gut microbiome and its potential role in the pathogenesis of inflammation and uremic toxicity ([@B48]). PCS also contributed to the development of insulin resistance in patients with CKD ([@B72]).

Lipopolysaccharide (LPS)-induced monocyte/macrophage activation could explain systemic inflammation and might be relevant to CKD/ESRD patients' conditions ([@B74]). [@B13] demonstrated in mouse model that the metabolic endotoxemia dysregulates the inflammatory character and activates body weight gain and diabetes. They also observed that lowering plasma LPS concentration could be an effective approach to regulate metabolic diseases such as diabetes ([@B13]).

We recently reported significant increases in inflammatory markers and markers of endothelial dysfunction in patients with diabetes, CKD, and ESRD on peritoneal dialysis, as well as correlations with levels of LPS and zonulin (a gut permeability marker; [@B17]; [@B57]; [@B70]). Human intestine also acts as an active player by presenting more precursors for fermentation due to disturbances in assimilation caused by uremia, followed by alterations in further processing related to changes in the composition of the fermenting flora ([@B66]). Deficiency in vitamin K and calcidiol is a common feature among patients with CKD and ESRD and is likely attributed to gut dysbiosis ([@B38]; [@B59]).

The colonic microbiome is an active site of methanol production, which might appear in the exhaled breath of subjects. The study of methanol breath content in ESRD on hemodialysis showed that methanol production could be substantially manipulated by the diet, which changed gut populations *per se* ([@B39]*)*.

Strong connection between gut pathobionts and CKD and ESRD in adult population is nowadays undoubtful fact. The next important questions to be answered in nephrology: how gut microbiome diversity impacted by primary renal disease and how it changes with progression of chronic renal impairment.

Pediatric Gut Microbiome
========================

The gastrointestinal tract (GIT) in neonates was thought to be almost sterile at birth and then rapidly colonized by bacteria shortly after delivery until an adult type composition was acquired around the first to the third year of life ([@B64]; [@B82]; [@B21]; [@B58]). This view has recently been challenged by reports of detection of diverse microbes in placenta, umbilical cord, amniotic fluid, and meconium ([@B33], [@B34]; [@B22]; [@B83]; [@B26]; [@B53]; [@B71]; [@B1]). It is now well established that during the first 3 years of life, children experience significant developmental changes that influence their health status as well as their immune system. Using sequential fecal analysis in a large cohort, human microbiome studies across North America, Africa, South America, and Europe, have made it apparent that gut microbiome is highly unstable during the first 3 years of life ([@B20]; [@B37]; [@B92]). The pattern of GIT microbiome development during child development is summarized in **Figure [1](#F1){ref-type="fig"}**.

![**The pattern of GIT microbiome development during a child development.** Pie charts are showing profusion of the bacterial taxa at different development stage. The gut-microbiome of the new born is primarily colonized by *Enterobacteria* ([@B26]). During the first month, *Bifidobacterial species* pre-dominate in the gut ([@B37]), but at around 4--6 months is convoyed by an increase of clostridial species. Later, the microbiome composition consists of mainly Bacteroidaceae, Lachnospiraceae, and Ruminococcaceae, which then remains stable into adulthood ([@B25]; [@B54]; [@B44]).](fmicb-07-00235-g001){#F1}

Gut Microbiome in Children with Kidney Disease
==============================================

The relationship between alterations in the gut microbiome and its possible involvement in the development of renal disease later in life is an important venue to be investigated. Consideration of GIT barrier structure and it changes in pathological conditions is necessary to understand relationships in the gut-renal axis in pediatrics. The maintenance of a healthy intestinal barrier is extremely important in children. There are multiple layers, which makeup the barrier between gut lumen and the rest of the body. The physical barrier is composed of gut microbiota, mucus, epithelial cells, and the innate and adaptive immune cells forming the gut-associated lymphoid tissue. The internal mucosal layer is dense and does not allow bacteria to penetrate, while the external mucus layer is the habitat of the gut microbiota. Each of those layers is compromised in a uremic condition (**Figure [2](#F2){ref-type="fig"}**).

![**Potential mechanisms by which gut microbiome affects kidney functions**.](fmicb-07-00235-g002){#F2}

As mentioned above, in a healthy body, normal gut microbiota competes with pathogens for space and energy resources, processes the molecules necessary to maintain mucosal integrity, and modulate the immunological activity of the deep barrier. In CKD and ESRD these functions are greatly compromised, based on animal and adult patient studies. Children with similar renal conditions are usually on a very specific diet, which might include food low in potassium, phosphorus, and salt. They may use phosphate binders and have restrictions on their water consumption. During infancy and early childhood, these restrictions could contribute to the development of an abnormal microbial population and weaken the first line of the gut barrier ([@B86]). This eventually leads to a "leaky gut syndrome." It also further compromises vitamin absorption necessary for growing bodies, including Vitamin D.

We also presume that many drugs or compounds used in the treatment of CKD and ESRD not only compromise gut microbiome, but may experience abnormal pharmacokinetics in the setting of abnormal intestinal permeability. In addition, the development of new pharmacological approaches to modulate the gut barrier components might contribute to prevention and treatment of extra-intestinal diseases, including kidney pathology.

Does early-life dysbiosis precede and play a role in disease pathogenesis, or simply originate because of the disease process itself? This question has been answered in a few diseases, including inflammatory bowel disease, obesity, and asthma ([@B4]). A paucity of data exists regarding how the gut-renal axis functions in a growing human with renal disease and what the role of the microbiome is in this process. Although, some data gathered from bench research and knowledge obtained from adult populations might be extrapolated to the pediatric population, the unique growing and constantly changing body deserves separate investigation.

One of the challenges in the study of the microbiome in any disease, including kidney disease, in early childhood is the greater variation in strain diversity documented during the first few months and years of life ([@B87]). Gut microbiota evolve and change during that growth. Data showed that individuals harbor their own specific *Bifidobacterial* microbiota even at the strain level. Thus, 96% of infants possessed their own individual specific *Bifidobacterial* microbiota ([@B7]).

Study of gut microbiome in children with renal disease should focus on four types of dysbiosis: loss of keystone taxa, loss of diversity, shifts in metabolic capacity, and blooms of pathogens. Both genetic and environmental factors should be taken into consideration while studying the development of gut microbiota composition ([@B73]). For example, one of the relevant papers from China found that gut microbiota was involved in melamine-induced renal injury in infants and children exposed to melamine-tainted milk. Melamine-induced renal toxicity was found to be mediated by the gut microbiota ([@B93]).

Preterm children need special consideration relevant to renal pathology. It is known that children born preterm have a high risk of the fast progression of CKD and low nephron numbers ([@B35]; [@B12]; [@B15]; [@B52]). Many infants begin life with a significant number of immature nephrons. They are exposed to a variety of external stressors such as hemodynamic alterations, nephrotoxic medications, infections, and suboptimal nutrition that can delay ongoing kidney development or cause nephron loss. Preterm infants and particularly very low birth weight infants are also at a disadvantage when it comes to the development of a healthy microbiome ([@B27]). The causes of their gut immaturity include preterm rupture of membranes, maternal infection, Cesarean delivery, perinatal and postnatal broad-spectrum antibiotic exposure, exposure to other gut-modifying medications (which might alter gut permeability), periods of fasting, intensive care infection control standards and exposure to resistant microbes and decreased acquaintance of human milk ([@B68]; [@B10]; [@B28]). [@B3] compared full-term breastfed vaginally delivered infants with preterm infants with regard to differences in representation of 18 microbial groups within gut flora. They demonstrated that when compared with full-term infants, preterm infants showed increased populations of facultative anaerobes such as *Enterococcus, Enterobacter*, and *Lactobacillus*, increased numbers of *Staphylococcus*, and decreased numbers of anaerobes such as *Bifidobacterium, Bacteroides*, and *Atopobium* ([@B46]; [@B9]).

The gut microbiome specifics in relationship to kidney compromised status were not well investigated.

Cross-sectional analysis of pediatric CKD data has revealed valuable information that better defines the prevalence of comorbid conditions and associated risk factors, but not gut microbiome. Hypertension, left ventricular hypertrophy, dyslipidemia, anemia, poor growth, and abnormal neurocognitive development are known comorbidities that accompany CKD ([@B90]), but pediatric gut microbiome in a uremic milieu is yet to be evaluated.

Conclusion
==========

Extensive microbiome research has been made possible by recent advances in gene sequencing and bioinformatics tools. Further study is required to decipher structures and functions of microbe population in the gut of pediatric AKI, CKD, and ESRD patients. This is a call for concerted efforts of pediatricians, pediatric nephrologists, immunologists, microbiologists, food and nutrition experts, and computational biologists to understand this clinical phenomenon and further applications in developing therapeutic regimens.
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